| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdd619b8a2cc2f110b9ee4dc8d896a17 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c300f81ab917b2e4a2996cf72b87ccf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c047c67cea80568df7856dedacbc9f03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c28eca7f67e0369df11b09f69ffaef04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccee43be06acbe1b9e845fc51177fb90 |
| publicationDate |
2005-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1575597-A1 |
| titleOfInvention |
Use of rimexolone in the treatment of dry eye |
| abstract |
Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of rimexolone to penetrate the cornea, a high portion of the drug remains on the surface of the eye, which is the primary locus of the inflammatory conditions associated with dry eye. This enables a very low concentration of drug to be utilized, which in turn reduces the potential for elevations of intraocular pressure and cataract formation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9732152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9950066-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9738714-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9750808-B2 |
| priorityDate |
2002-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |